Company intelligence / Profile preview

Dogwood Therapeutics, Inc.

Atlanta, Georgia, United Statesdwtx.com ↗

Ownership: Public · DWTX
Employees: ~12
Development stage: Phase 2

Overview

Currently conducting Phase 2b trial for Halneuron in CINP with interim data expected in Q4 2025. Previous Phase 2 clinical trial demonstrated statistically significant reduction in cancer-related pain with acceptable safety profile. IMC-2 has shown successful reduction of fatigue associated with Long COVID in clinical trials.

Therapeutic areas: OncologyRheumatologyNeurologyInfectious Diseases
Modalities: Small moleculesCombination therapiesSodium channel blockers
Industry: Biotech

Drug pipeline

1 asset

tetrodotoxin

Partnerships

Exploring partnerships for IMC-1 Phase 3 development

Financials

Market cap: $63.2M
Total revenue: $0
Enterprise value: $53.7M

Beyond the preview

Go deeper on Dogwood Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dogwood Therapeutics, Inc..

Explore the full profile